Adicet Bio, Inc.

ACETSEC EDGAR

Pharmaceutical Preparations(DE)CIK: 1720580

Concept	FY2025	FY2024	FY2023	FY2022	FY2021
Research and Development Expense	$99.3M	$106.0M	$71.2M	$48.9M	$34.3M
Operating Expenses	$127.6M	$152.0M	$97.5M	$71.2M	$57.1M
Operating Income (Loss)	-$127.6M	-$152.0M	-$72.6M	-$61.4M	-$39.2M
Interest Expense	$4.0K	$25.0K	$80.0K	$176.0K	$134.0K
Other Nonoperating Income (Expense)	-$217.0K	-$573.0K	-$919.0K	-$606.0K	-$953.0K
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest	-$117.1M	-$142.7M	-$69.8M	-$62.1M	-$39.5M
Income Tax Expense (Benefit)	$0.00	$0.00	$0.00	-$125.0K	-$2.8M
Net Income (Loss) Attributable to Parent	-$117.1M	-$142.7M	-$69.8M	-$62.0M	-$36.7M
Earnings Per Share, Basic	-$21.33	-$3.31	-$1.70	-$2.00	—
Earnings Per Share, Diluted	-$21.33	-$3.31	-$1.70	-$2.00	—

Concept	FY2025	FY2024	FY2023	FY2022	FY2021
Assets	$220.2M	$207.3M	$330.7M	$338.9M	$153.8M
Assets, Current	$180.1M	$162.3M	$261.0M	$282.4M	$100.3M
Cash and Cash Equivalents, at Carrying Value	$56.5M	$159.7M	$257.7M	$277.5M	$84.3M
Liabilities	$33.6M	$37.1M	$38.4M	$35.8M	$44.0M
Liabilities, Current	$19.4M	$19.3M	$19.7M	$16.3M	$22.5M
Accounts Payable, Current	$4.8M	$2.6M	$4.4M	$3.3M	$1.6M
Stockholders' Equity Attributable to Parent	$170.2M	$292.3M	$303.1M	$109.8M

Concept	FY2025	FY2024	FY2023	FY2022	FY2021
Net Cash Provided by (Used in) Operating Activities	-$92.4M	-$93.7M	-$44.8M	-$51.1M	-$41.6M
Net Cash Provided by (Used in) Investing Activities	-$119.2M	-$4.5M	-$16.8M	-$2.8M	$115.2M
Net Cash Provided by (Used in) Financing Activities	$111.3M	$236.0K	$41.5M	$242.7M	$303.0K
Payments to Acquire Property, Plant, and Equipment	$1.1M	$4.5M	$16.8M	$13.0M	$990.0K
Payments for Repurchase of Common Stock	—	—	—	—	$15.0M

Access SEC EDGAR data via REST API. Free tier available.

from sec_edgar import SecEdgar

api = SecEdgar("YOUR_KEY")
api.revenue("AAPL", limit=5)